A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined Significance
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND: A monoclonal gammopathy of undetermined significance (MGUS) occurs in up to 2 percent of persons 50 years of age or older. Reliable predictors of progression have not been identified, and information on prognosis is limited. METHODS: We identified 1384 patients residing in southeastern Minnesota in whom MGUS was diagnosed at the Mayo Clinic from 1960 through 1994. The primary end point was progression to multiple myeloma or another plasma-cell cancer. RESULTS: During 11,009 person-years of follow-up, MGUS progressed in 115 of the 1384 patients to multiple myeloma, IgM lymphoma, primary amyloidosis, macroglobulinemia, chronic lymphocytic leukemia, or plasmacytoma (relative risk of progression, 25.0, 2.4, 8.4, 46.0, 0.9, and 8.5, respectively). The overall relative risk of progression was 7.3 in these patients as compared with the white population of the Iowa Surveillance, Epidemiology, and End Results program. In 32 additional patients, the monoclonal protein concentration increased to more than 3 g per deciliter or the percentage of plasma cells in the bone marrow increased to more than 10 percent (smoldering multiple myeloma) but without progression to overt myeloma or related disorders. The cumulative probability of progression was 12 percent at 10 years, 25 percent at 20 years, and 30 percent at 25 years. The initial concentration of serum monoclonal protein was a significant predictor of progression at 20 years. CONCLUSIONS: The risk of progression of MGUS to multiple myeloma or related disorders is about 1 percent per year.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“MGUS progresses to multiple myeloma or related malignancy a rate of 1% per year.16,17”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [16]
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Asymptotically Efficient Rank Invariant Test Procedures
Peto, R., & Peto, J. (1972) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2344317 · Cited by 3,393
Gooley, T. A., Leisenring, W., Crowley, J., & Storer, B. E. (1999) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19990330)18:6<695::aid-sim60>3.0.co;2-o · Cited by 2,688
History of the Rochester Epidemiology Project
Melton, L. J. (1996) · Mayo Clinic Proceedings · doi:10.4065/71.3.266 · Cited by 1,443
Self-citationKyle, R., Linos, A., Beard, C., Linke, R., Gertz, M., O'Fallon, W., & Kurland, L. (1992) · Blood · doi:10.1182/blood.v79.7.1817.1817 · Cited by 657
Self-citationMonoclonal gammopathy of undetermined significance
Kyle, R. A. (1978) · The American Journal of Medicine · doi:10.1016/0002-9343(78)90522-3 · Cited by 607
Self-citationFrequency of Pathological Proteins (M‐components) in 6,995 Sera from an Adult Population
AXELSSON, U., BACHMANN, R., & HÄLLÉN, J. (1966) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1966.tb05453.x · Cited by 436
“Benign” Monoclonal Gammopathy—After 20 to 35 Years of Follow-Up
KYLE, R. A. (1993) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)60015-9 · Cited by 338
Self-citationThe Analysis of Mortality by the Subject-Years Method
Berry, G. (1983) · Biometrics · doi:10.2307/2530817 · Cited by 278
Research works printed but not linked: 4
- Hallen J, 1966, Acta Med Scand Suppl, 462, 1
- Kyle RA, Katzmann JA. Immunochemical characterization of immunoglobulins. In: Rose NR, Conway de Macario E, Folds JD, Lane HC, Nakamura RM, eds. Manual of clinical laboratory immunology. 5th ed. Washington, D.C.: ASM Press, 1997:156-76.
- Kyle RA, 1999, Blood, 94, 537a
- Fonseca R, 1999, Blood, 94, 663a
Cited by
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
Rajkumar, S. V., Dimopoulos, M. A., Palumbo, A., Blade, J., Merlini, G., Mateos, M.-V., Kumar, S., Hillengass, J., Kastritis, E., Richardson, P., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70442-5 · Cited by 4,978
Self-citationAge-related clonal hematopoiesis associated with adverse outcomes
Jaiswal, S., Fontanillas, P., Flannick, J., Manning, A., Grauman, P. V., Mar, B. G., Lindsley, R. C., Mermel, C. H., Burtt, N., Chavez, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408617 · Cited by 4,841
The International Myeloma Working Group (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04355.x · Cited by 2,321
“In addition, the presence of small amounts of monoclonal light chain in the urine did not predict progression (Kyle et al, 2002).”
BackgroundSwann, J. B., & Smyth, M. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31405 · Cited by 1,447
Gertz, M. A., Comenzo, R., Falk, R. H., Fermand, J. P., Hazenberg, B. P., Hawkins, P. N., Merlini, G., Moreau, P., Ronco, P., Sanchorawala, V., et al. (2005) · American Journal of Hematology · doi:10.1002/ajh.20381 · Cited by 1,428
“The presence of a monoclonal gammopathy should not be used as the only evidence of AL, because a small fraction of patients with familial (AF), secondary (AA), and senile systemic amyloidosis (SSA) will have an incidental monoclonal gammopathy [35] and evidence of clonal plasma cell dyscrasia associated with amyloidos…”
BackgroundPrevalence of monoclonal gammopathy of undetermined significance
Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Larson, D. R., Plevak, M. F., Offord, J. R., Dispenzieri, A., Katzmann, J. A., & Melton, L. J. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054494 · Cited by 1,423
Self-citationKyle, R. A., & Rajkumar, S. V. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041875 · Cited by 1,296
Self-citationKumar, S. K., Rajkumar, V., Kyle, R. A., van Duin, M., Sonneveld, P., Mateos, M.-V., Gay, F., & Anderson, K. C. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.46 · Cited by 1,177
“Increased occurrence of del(17p) and translocation t(8;14), linking the IGH enhancer on chromo some 14 with the MYC oncogene, is clearly associ ated with progression from newly diagnosed multiple myeloma to refractory disease and plasma cell leukaemia.”
BackgroundSelf-citationThe molecular classification of multiple myeloma
Zhan, F., Huang, Y., Colla, S., Stewart, J. P., Hanamura, I., Gupta, S., Epstein, J., Yaccoby, S., Sawyer, J., Burington, B., et al. (2006) · Blood · doi:10.1182/blood-2005-11-013458 · Cited by 1,133
Landgren, O., Kyle, R. A., Pfeiffer, R. M., Katzmann, J. A., Caporaso, N. E., Hayes, R. B., Dispenzieri, A., Kumar, S., Clark, R. J., Baris, D., et al. (2009) · Blood · doi:10.1182/blood-2008-12-194241 · Cited by 1,127
Self-citationClinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma
Kyle, R. A., Remstein, E. D., Therneau, T. M., Dispenzieri, A., Kurtin, P. J., Hodnefield, J. M., Larson, D. R., Plevak, M. F., Jelinek, D. F., Fonseca, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070389 · Cited by 921
Self-citationKyle, R. A., Durie, B. G. M., Rajkumar, S. V., Landgren, O., Blade, J., Merlini, G., Kröger, N., Einsele, H., Vesole, D. H., Dimopoulos, M., et al. (2010) · Leukemia · doi:10.1038/leu.2010.60 · Cited by 888
Self-citationKyle, R. A., & Rajkumar, S. V. (2008) · Blood · doi:10.1182/blood-2007-10-078022 · Cited by 855
Self-citationMultiple myeloma: 2022 update on diagnosis, risk stratification, and management
Rajkumar, S. V. (2022) · American Journal of Hematology · doi:10.1002/ajh.26590 · Cited by 883
“MGUS progresses to multiple myeloma or related malignancy at a rate of 1% per year.(17,18) Since MGUS is asymptomatic, over 50% of individuals who are diagnosed with MGUS have had the condition for over 10 years prior to the clinical diagnosis.”
BackgroundSelf-citationMultiple myeloma: 2020 update on diagnosis, risk‐stratification and management
Rajkumar, S. V. (2020) · American Journal of Hematology · doi:10.1002/ajh.25791 · Cited by 789
“And, MGUS progresses to multiple myeloma or related malignancy at a rate of 1% per year.(15,16) Note, MGUS is asymptomatic, and over 50% of individuals”
BackgroundSelf-citationMultiple Myeloma: Diagnosis and Treatment
Rajkumar, S. V., & Kumar, S. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2015.11.007 · Cited by 812
“Trisomies and IgH translocations are considered primary cytogenetic abnormalities and occur at the time of establishment of MGUS.”
BackgroundInfluentialSelf-citationMultiple myeloma epidemiology and survival: A unique malignancy
Kazandjian, D. (2016) · Seminars in Oncology · doi:10.1053/j.seminoncol.2016.11.004 · Cited by 765
Cancer statistics for African Americans, 2019
DeSantis, C. E., Miller, K. D., Goding Sauer, A., Jemal, A., & Siegel, R. L. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21555 · Cited by 743
Increased Prevalence and Mortality in Undiagnosed Celiac Disease
Rubio–Tapia, A., Kyle, R. A., Kaplan, E. L., Johnson, D. R., Page, W., Erdtmann, F., Brantner, T. L., Kim, W. R., Phelps, T. K., Lahr, B. D., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.03.059 · Cited by 767
Self-citationRajkumar, S. V., Kyle, R. A., Therneau, T. M., Melton, L. J., Bradwell, A. R., Clark, R. J., Larson, D. R., Plevak, M. F., Dispenzieri, A., & Katzmann, J. A. (2005) · Blood · doi:10.1182/blood-2005-03-1038 · Cited by 747
Self-citationRaab, M. S., Podar, K., Breitkreutz, I., Richardson, P. G., & Anderson, K. C. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60221-x · Cited by 697
Genetics and Cytogenetics of Multiple Myeloma
Fonseca, R., Barlogie, B., Bataille, R., Bastard, C., Bergsagel, P. L., Chesi, M., Davies, F. E., Drach, J., Greipp, P. R., Kirsch, I. R., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2876 · Cited by 687
“are those at risk of evolution to MM (14).”
BackgroundInfluentialMisdiagnosis of Hereditary Amyloidosis as AL (Primary) Amyloidosis
Lachmann, H. J., Booth, D. R., Booth, S. E., Bybee, A., Gilbertson, J. A., Gillmore, J. D., Pepys, M. B., & Hawkins, P. N. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013354 · Cited by 680
Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance
Kyle, R. A., Larson, D. R., Therneau, T. M., Dispenzieri, A., Kumar, S., Cerhan, J. R., & Rajkumar, S. V. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709974 · Cited by 647
Self-citationKumar, S. K., Mikhael, J. R., Buadi, F. K., Dingli, D., Dispenzieri, A., Fonseca, R., Gertz, M. A., Greipp, P. R., Hayman, S. R., Kyle, R. A., et al. (2009) · Mayo Clinic Proceedings · doi:10.4065/mcp.2009.0603 · Cited by 628
“Patients with MGUS have a small risk of progression (1% per year) to MM and require only observation.(22-24) In some individuals, an intervening phase of smoldering MM (SMM) can be identified, which is characterized by a higher burden of malignant plasma cells and higher levels of monoclonal proteins.”
BackgroundSelf-citationMonoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia
Rawstron, A. C., Bennett, F. L., O'Connor, S. J. M., Kwok, M., Fenton, J. A. L., Plummer, M., de Tute, R., Owen, R. G., Richards, S. J., Jack, A. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa075290 · Cited by 613
Cancer statistics for African American/Black People 2022
Giaquinto, A. N., Miller, K. D., Tossas, K. Y., Winn, R. A., Jemal, A., & Siegel, R. L. (2022) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21718 · Cited by 574
Advances in biology of multiple myeloma: clinical applications
Hideshima, T., Bergsagel, P. L., Kuehl, W. M., & Anderson, K. C. (2004) · Blood · doi:10.1182/blood-2004-01-0037 · Cited by 582
“8,26 Mutually exclusive activating mutations of K- or N-Ras (or FGFR3 when there is a t(4;14) translocation) are rare or absent in MGUS, whereas Ras mutations are present in 30% to 40% of early MM, and FGFR3 mutations occur more frequently in advanced MM.”
BackgroundInfluentialA monoclonal gammopathy precedes multiple myeloma in most patients
Weiss, B. M., Abadie, J., Verma, P., Howard, R. S., & Kuehl, W. M. (2009) · Blood · doi:10.1182/blood-2008-12-195008 · Cited by 569
“Bone marrow plasma cells, % (range) 50 (2-95) 50 (1-95) .”
Pérez-Persona, E., Vidriales, M.-B., Mateo, G., García-Sanz, R., Mateos, M.-V., de Coca, A. G., Galende, J., Martín-Nuñez, G., Alonso, J. M., de las Heras, N., et al. (2007) · Blood · doi:10.1182/blood-2007-05-088443 · Cited by 579
“Less than 2 g/dL MGUS and less than 3 g/dL SMM Nr 11/279 (4) .”
BackgroundMolecular Pathogenesis and a Consequent Classification of Multiple Myeloma
Bergsagel, P. L., & Kuehl, W. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.021 · Cited by 556
Kim, J. H., Kim, J. W., Kim, Y. N., Kim, H. I., Kim, J. Y., Kwon, G. Y., Kim, K., & Jang, H. R. (2015) · Case Reports in Nephrology and Dialysis · doi:10.1159/000439267 · Cited by 538
Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management
Rajkumar, S. V. (2024) · American Journal of Hematology · doi:10.1002/ajh.27422 · Cited by 534
Self-citationLeukemia-associated somatic mutations drive distinct patterns of age-related clonal hemopoiesis
McKerrell, T., Park, N., Moreno, T., Grove, C. S., Ponstingl, H., Stephens, J., Crawley, C., Craig, J., Scott, M. A., Hodkinson, C., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.02.005 · Cited by 534
“Ce well established in hematological malignancies, whose clonal history can be traced back for several years or even decades (Ford et al., 1998; Kyle et al., 2002).”
BackgroundMikhael, J. R., Dingli, D., Roy, V., Reeder, C. B., Buadi, F. K., Hayman, S. R., Dispenzieri, A., Fonseca, R., Sher, T., Kyle, R. A., et al. (2013) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2013.01.019 · Cited by 500
“Indeed, monoclonal gammopathy of undetermined significance (MGUS) is a generally benign condition, with a transformation rate to symptomatic plasma cell disorders of approximately 1% to 2% annually, and is common, with an incidence of 5% in individuals older than 70 years.(3,4) Between MGUS and MM is asymptomatic MM (…”
BackgroundSelf-citationRossi, D., Rasi, S., Spina, V., Bruscaggin, A., Monti, S., Ciardullo, C., Deambrogi, C., Khiabanian, H., Serra, R., Bertoni, F., et al. (2013) · Blood · doi:10.1182/blood-2012-09-458265 · Cited by 467
Barlogie, B., Shaughnessy, J., Tricot, G., Jacobson, J., Zangari, M., Anaissie, E., Walker, R., & Crowley, J. (2004) · Blood · doi:10.1182/blood-2003-04-1045 · Cited by 464
Multiple myeloma: 2016 update on diagnosis, risk‐stratification, and management
Rajkumar, S. V. (2016) · American Journal of Hematology · doi:10.1002/ajh.24402 · Cited by 456
Self-citationDispenzieri, A., Kyle, R. A., Katzmann, J. A., Therneau, T. M., Larson, D., Benson, J., Clark, R. J., Melton, L. J., Gertz, M. A., Kumar, S. K., et al. (2008) · Blood · doi:10.1182/blood-2007-08-108357 · Cited by 433
“Serum M protein, median g/L (range) 29 (5-54)”
Self-citationDiagnostic criteria for monoclonal B‐cell lymphocytosis
Marti, G. E., Rawstron, A. C., Ghia, P., Hillmen, P., Houlston, R. S., Kay, N., Schleinitz, T. A., Caporaso, N., & The International Familial CLL Consortium (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05550.x · Cited by 412
“One group (Kyle & Rajkumar, 1999; Kyle et al, 2002) established a significant relationship between multiple myeloma (MM) and monoclonal gammopathy of undetermined significance (MGUS).”
BackgroundMalard, F., Neri, P., Bahlis, N. J., Terpos, E., Moukalled, N., Hungria, V. T. M., Manier, S., & Mohty, M. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00529-7 · Cited by 337
The role of Dickkopf-1 in bone development, homeostasis, and disease
Pinzone, J. J., Hall, B. M., Thudi, N. K., Vonau, M., Qiang, Y.-W., Rosol, T. J., & Shaughnessy, J. D. (2009) · Blood · doi:10.1182/blood-2008-03-145169 · Cited by 408
“We confirmed that pretreatment with rDKK1 completely abolished Wnt3a-induced OPG mRNA and protein expression by mouse and human osteoblasts, and that coculture of osteoblasts with either a DKK1-expressing MM cell line or primary MM cells diminished OPG expression in the osteoblasts.68 Moreover, bone marrow sera from M…”
BackgroundInfluentialC1 inhibitor deficiency: consensus document
Gompels, M. M., Lock, R. J., Abinun, M., Bethune, C. A., Davies, G., Grattan, C., Fay, A. C., Longhurst, H. J., Morrison, L., Price, A., et al. (2005) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2005.02726.x · Cited by 411
Usmani, S. Z., Heuck, C., Mitchell, A., Szymonifka, J., Nair, B., Hoering, A., Alsayed, Y., Waheed, S., Haider, S., Restrepo, A., et al. (2012) · Haematologica · doi:10.3324/haematol.2012.065698 · Cited by 394
Dispenzieri, A., Katzmann, J. A., Kyle, R. A., Larson, D. R., Melton, L. J., Colby, C. L., Therneau, T. M., Clark, R., Kumar, S. K., Bradwell, A., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60482-5 · Cited by 394
Self-citationBladé, J., Fernández de Larrea, C., Rosiñol, L., Cibeira, M. T., Jiménez, R., & Powles, R. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.9290 · Cited by 387
Zhan, F., Barlogie, B., Arzoumanian, V., Huang, Y., Williams, D. R., Hollmig, K., Pineda-Roman, M., Tricot, G., van Rhee, F., Zangari, M., et al. (2007) · Blood · doi:10.1182/blood-2006-07-037077 · Cited by 381
Screening Panels for Detection of Monoclonal Gammopathies
Katzmann, J. A., Kyle, R. A., Benson, J., Larson, D. R., Snyder, M. R., Lust, J. A., Rajkumar, S. V., & Dispenzieri, A. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2009.126664 · Cited by 348
Self-citationUpdated Diagnostic Criteria and Staging System for Multiple Myeloma
Rajkumar, S. V. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_159009 · Cited by 350
Self-citationGenomic abnormalities in monoclonal gammopathy of undetermined significance
Fonseca, R., Bailey, R. J., Ahmann, G. J., Rajkumar, S. V., Hoyer, J. D., Lust, J. A., Kyle, R. A., Gertz, M. A., Greipp, P. R., & Dewald, G. W. (2002) · Blood · doi:10.1182/blood.v100.4.1417.h81602001417_1417_1424 · Cited by 348
Self-citationLandgren, O., Gridley, G., Turesson, I., Caporaso, N. E., Goldin, L. R., Baris, D., Fears, T. R., Hoover, R. N., & Linet, M. S. (2006) · Blood · doi:10.1182/blood-2005-08-3449 · Cited by 333
Fracture Risk With Multiple Myeloma: A Population-Based Study
Melton, L. J., Kyle, R. A., Achenbach, S. J., Oberg, A. L., & Rajkumar, S. V. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.041131 · Cited by 332
“The discrepancy may be caused in part by classification of some osteoporotic vertebral fractures as pathological in the setting of myeloma but not in patients with MGUS who, by definition, do not have lytic bone lesions.((35)) Despite the 2-fold increase in osteoporotic fractures, generalized osteoporosis would not se…”
BackgroundSelf-citationMultiple myeloma: A review of the epidemiologic literature
Alexander, D. D., Mink, P. J., Adami, H.-O., Cole, P., Mandel, J. S., Oken, M. M., & Trichopoulos, D. (2007) · International Journal of Cancer · doi:10.1002/ijc.22718 · Cited by 321
Long-term follow-up of IgM monoclonal gammopathy of undetermined significance
Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Remstein, E. D., Offord, J. R., Larson, D. R., Plevak, M. F., & Melton, L. J. (2003) · Blood · doi:10.1182/blood-2003-03-0801 · Cited by 325
Self-citationRisk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria
Lakshman, A., Rajkumar, S. V., Buadi, F. K., Binder, M., Gertz, M. A., Lacy, M. Q., Dispenzieri, A., Dingli, D., Fonder, A. L., Hayman, S. R., et al. (2018) · Blood Cancer Journal · doi:10.1038/s41408-018-0077-4 · Cited by 303
Self-citationGuidelines on the diagnosis and management of multiple myeloma 2005
Smith, A., Wisloff, F., Samson, D., & the UK Myeloma Forum, N. M. S. G. A. B. C. F. S. I. H. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05867.x · Cited by 311
Multiple Myeloma: Clinical Review and Diagnostic Imaging
Angtuaco, E. J. C., Fassas, A. B. T., Walker, R., Sethi, R., & Barlogie, B. (2004) · Radiology · doi:10.1148/radiol.2311020452 · Cited by 299
Walker, B. A., Wardell, C. P., Melchor, L., Brioli, A., Johnson, D. C., Kaiser, M. F., Mirabella, F., Lopez-Corral, L., Humphray, S., Murray, L., et al. (2014) · Leukemia · doi:10.1038/leu.2013.199 · Cited by 283
Rajkumar, S. V. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.63 · Cited by 289
Self-citationChng, W.-J., Huang, G. F., Chung, T. H., Ng, S. B., Gonzalez-Paz, N., Troska-Price, T., Mulligan, G., Chesi, M., Bergsagel, P. L., & Fonseca, R. (2011) · Leukemia · doi:10.1038/leu.2011.53 · Cited by 270
Whole-body (18)F-FDG PET identifies high-risk myeloma.
Durie, B. G. M., Waxman, A. D., D'Agnolo, A., & Williams, C. M. (2002) · PubMed · Cited by 272
Walker, B. A., Wardell, C. P., Chiecchio, L., Smith, E. M., Boyd, K. D., Neri, A., Davies, F. E., Ross, F. M., & Morgan, G. J. (2011) · Blood · doi:10.1182/blood-2010-04-279539 · Cited by 267
“29 The nonintensive arm consisted of older patients who were treated with either (1) attenuated cyclophosphamide, thalidomide, and dexamethasone or (2) melphalan and prednisolone.”
MethodUnderstanding and interpreting serum protein electrophoresis.
O'Connell, T. X., Horita, T. J., & Kasravi, B. (2005) · PubMed · Cited by 268
Jinushi, M., Vanneman, M., Munshi, N. C., Tai, Y.-T., Prabhala, R. H., Ritz, J., Neuberg, D., Anderson, K. C., Carrasco, D. R., & Dranoff, G. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711293105 · Cited by 256
“MGUS evolves at a frequency of 1% per year to full-blown multiple myeloma (MM), a lethal malignancy in which dysregulated plasma cell homeostasis provokes bone marrow compromise, osteolytic lesions, metabolic perturbations, and kidney damage (2, 3).”
BackgroundChim, C.-S., Fung, T.-K., Cheung, W.-C., Liang, R., & Kwong, Y.-L. (2004) · Blood · doi:10.1182/blood-2003-06-2007 · Cited by 246
“MGUS is a precursor of myeloma, and the median interval from discovery of the M-protein to the development of myeloma might be up to 10 years.(3,4) The binding of cytokines to their receptors results in the dimerization of receptor complexes and activation of the Janus family of protein tyrosine kinases (JAKs),(5-7) f…”
BackgroundSerum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma
Larsen, J. T., Kumar, S. K., Dispenzieri, A., Kyle, R. A., Katzmann, J. A., & Rajkumar, S. V. (2013) · Leukemia · doi:10.1038/leu.2012.296 · Cited by 239
Self-citationMonoclonal CD5+ and CD5- B-lymphocyte expansions are frequent in the peripheral blood of the elderly
Ghia, P., Prato, G., Scielzo, C., Stella, S., Geuna, M., Guida, G., & Caligaris-Cappio, F. (2004) · Blood · doi:10.1182/blood-2003-09-3277 · Cited by 239
Rajkumar, S. V., Gupta, V, Fonseca, R., Dispenzieri, A., Gonsalves, W. I., Larson, D., Ketterling, R. P., Lust, J. A., Kyle, R. A., & Kumar, S. K. (2013) · Leukemia · doi:10.1038/leu.2013.86 · Cited by 239
Self-citationCuring myeloma at last: defining criteria and providing the evidence
Barlogie, B., Mitchell, A., van Rhee, F., Epstein, J., Morgan, G. J., & Crowley, J. (2014) · Blood · doi:10.1182/blood-2014-07-552059 · Cited by 235
Multiple myeloma: 2018 update on diagnosis, risk‐stratification, and management
Rajkumar, S. V. (2018) · American Journal of Hematology · doi:10.1002/ajh.25117 · Cited by 209
“MGUS progresses to multiple myeloma or related malignancy a rate of 1% per year.(16,17) Since MGUS is asymptomatic, over 50% of individuals who are diagnosed with MGUS have had the condition for over 10 years prior to the clinical diagnosis.”
BackgroundSelf-citationInsights into the multistep transformation of MGUS to myeloma using microarray expression analysis
Davies, F. E., Dring, A. M., Li, C., Rawstron, A. C., Shammas, M. A., O'Connor, S. M., Fenton, J. A. L., Hideshima, T., Chauhan, D., Tai, I. T., et al. (2003) · Blood · doi:10.1182/blood-2003-01-0016 · Cited by 223
“4 INTRODUCTION Long-term follow-up of individuals with monoclonal gammopathy of uncertain significance (MGUS) has shown that approximately 1% of cases progress to symptomatic multiple myeloma annually.(1) In addition to presenting with classical clinical features it is well recognised that towards the end of its natur…”
BackgroundClinically relevant end points and new drug approvals for myeloma
Anderson, K. C., Kyle, R. A., Rajkumar, S. V., Stewart, A. K., Weber, D., Richardson, P., & Myeloma, O. B. O. T. A. /. P. O. C. E. I. M. (2008) · Leukemia · doi:10.1038/sj.leu.2405016 · Cited by 225
Self-citationMonoclonal gammopathy of undetermined significance
Kyle, R. A., & Vincent Rajkumar, S. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06235.x · Cited by 223
“Data originally reported by Kyle et al (2002a). ª 2006 The Authors Journal Compilation ª 2006 Blackwell Publishing Ltd, British Journal of Haematology, 134, 573–589 579 the other hand, serological testing for H. pylori showed that 30% of 93 MGUS patients, who were residents of Olmsted County, MN,…”
BackgroundMethodInfluentialSelf-citationInherited predisposition to CLL is detectable as subclinical monoclonal B-lymphocyte expansion
Rawstron, A. C., Yuille, M. R., Fuller, J., Cullen, M., Kennedy, B., Richards, S. J., Jack, A. S., Matutes, E., Catovsky, D., Hillmen, P., et al. (2002) · Blood · doi:10.1182/blood-2002-03-0892 · Cited by 223
Dhodapkar, M. V., Krasovsky, J., Osman, K., & Geller, M. D. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20031030 · Cited by 217
“Our finding that there is a vigorous preneoplasia-specific effector T cell response in the MGUS marrow raises important questions about the potential impact of this immune response on the preneoplastic cells, and perhaps more importantly, their microenvironment (1).”
BackgroundInfluentialSethi, S., & Fervenza, F. C. (2011) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2011.06.005 · Cited by 213
Multiple myeloma: 2014 Update on diagnosis, risk‐stratification, and management
Rajkumar, S. V. (2014) · American Journal of Hematology · doi:10.1002/ajh.23810 · Cited by 208
Self-citationLandgren, O., Graubard, B. I., Katzmann, J. A., Kyle, R. A., Ahmadizadeh, I., Clark, R., Kumar, S. K., Dispenzieri, A., Greenberg, A. J., Therneau, T. M., et al. (2014) · Leukemia · doi:10.1038/leu.2014.34 · Cited by 208
Self-citationBida, J. P., Kyle, R. A., Therneau, T. M., Melton, L. J., Plevak, M. F., Larson, D. R., Dispenzieri, A., Katzmann, J. A., & Rajkumar, S. V. (2009) · Mayo Clinic Proceedings · doi:10.4065/84.8.685 · Cited by 202
Self-citationMailankody, S., Pfeiffer, R. M., Kristinsson, S. Y., Korde, N., Bjorkholm, M., Goldin, L. R., Turesson, I., & Landgren, O. (2011) · Blood · doi:10.1182/blood-2011-05-355743 · Cited by 200
Korde, N., Kristinsson, S. Y., & Landgren, O. (2011) · Blood · doi:10.1182/blood-2011-01-270140 · Cited by 199
“Either of these can coexist with deletion of chromosome 13, although this abnormality most commonly ( 80% to 90% of patients) occurs with the t(4;14), t(14;16), and t(14;20) IgH translocations.”
BackgroundInfluentialGenetic events in the pathogenesis of multiple myeloma
Chng, W. J., Glebov, O., Bergsagel, P. L., & Kuehl, W. M. (2007) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2007.08.004 · Cited by 188
Prevalence of Monoclonal Gammopathy of Undetermined Significance Among Men in Ghana
Landgren, O., Katzmann, J. A., Hsing, A. W., Pfeiffer, R. M., Kyle, R. A., Yeboah, E. D., Biritwum, R. B., Tettey, Y., Adjei, A. A., Larson, D. R., et al. (2007) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)61089-6 · Cited by 194
Self-citationKyle, R. A., Therneau, T. M., Rajkumar, S. V., Larson, D. R., Plevak, M. F., & Melton, L. J. (2004) · Mayo Clinic Proceedings · doi:10.4065/79.7.859 · Cited by 194
Self-citationCaligaris-Cappio, F., & Ghia, P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.4393 · Cited by 194
Myeloma as a model for the process of metastasis: implications for therapy
Ghobrial, I. M. (2012) · Blood · doi:10.1182/blood-2012-01-379024 · Cited by 188
Dhodapkar, M. V., Sexton, R., Waheed, S., Usmani, S., Papanikolaou, X., Nair, B., Petty, N., Shaughnessy, J. D., Hoering, A., Crowley, J., et al. (2014) · Blood · doi:10.1182/blood-2013-07-515239 · Cited by 192
Rajkumar, S. V., Dispenzieri, A., & Kyle, R. A. (2006) · Mayo Clinic Proceedings · doi:10.4065/81.5.693 · Cited by 192
“However, the risk of progression to myeloma or related malignancy is much higher in SMM compared with MGUS: 1% per year vs 10% to 20% per year, respectively.(4,15,32,33) This difference in the risk of progression means that patients with SMM and MGUS should be managed differently in terms of frequency of follow-up, de…”
BackgroundSelf-citationMurray, D. L., Puig, N., Kristinsson, S., Usmani, S. Z., Dispenzieri, A., Bianchi, G., Kumar, S., Chng, W. J., Hajek, R., Paiva, B., et al. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00408-4 · Cited by 175
Self-citationMills, J. R., Kohlhagen, M. C., Dasari, S., Vanderboom, P. M., Kyle, R. A., Katzmann, J. A., Willrich, M. A. V., Barnidge, D. R., Dispenzieri, A., & Murray, D. L. (2016) · Clinical Chemistry · doi:10.1373/clinchem.2015.253740 · Cited by 182
Self-citationJungbluth, A. A., Ely, S., DiLiberto, M., Niesvizky, R., Williamson, B., Frosina, D., Chen, Y.-T., Bhardwaj, N., Chen-Kiang, S., Old, L. J., et al. (2005) · Blood · doi:10.1182/blood-2004-12-4931 · Cited by 182
“RT-PCR, n 7 6/7 (86) 7/7 (100) 1/5 (20)”
Cell of Origin and Genetic Alterations in the Pathogenesis of Multiple Myeloma
Barwick, B. G., Gupta, V. A., Vertino, P. M., & Boise, L. H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01121 · Cited by 163
“This is a major problem as MGUS is present in 3% of the population over 50 years of age, and progresses to multiple myeloma at a rate of ∼1% per annum (21, 22).”
BackgroundTargeted and Untargeted Proteomics Approaches in Biomarker Development
Sobsey, C. A., Ibrahim, S., Richard, V. R., Gaspar, V., Mitsa, G., Lacasse, V., Zahedi, R. P., Batist, G., & Borchers, C. H. (2020) · PROTEOMICS · doi:10.1002/pmic.201900029 · Cited by 171
Membranoproliferative Glomerulonephritis Secondary to Monoclonal Gammopathy
Sethi, S., Zand, L., Leung, N., Smith, R. J. H., Jevremonic, D., Herrmann, S. S., & Fervenza, F. C. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.06760909 · Cited by 181
van de Donk, N. W. C. J., Palumbo, A., Johnsen, H. E., Engelhardt, M., Gay, F., Gregersen, H., Hajek, R., Kleber, M., Ludwig, H., Morgan, G., et al. (2014) · Haematologica · doi:10.3324/haematol.2013.100552 · Cited by 176
“8 years for age- and sex-matched Minnesota residents.(4) Excess mortality is not only caused by development of MM and other lymphoproliferative diseases, but there is also an increased risk of dying of myeloid malignancies, non-hematologic cancers, bacterial infections, heart disorders, liver diseases, and renal disor…”
BackgroundInfluentialMGUS to myeloma: a mysterious gammopathy of underexplored significance
Dhodapkar, M. V. (2016) · Blood · doi:10.1182/blood-2016-09-692954 · Cited by 171
“Nonetheless, these criteria have served the field well to harmonize clinical research, and they identify cohorts with distinct risks of progression to myeloma requiring therapy (1% per year for MGUS and 10% per year for AMM).(7,8) Measures of tumor bulk (level of M spike, free light chains), nature of IgH type (IgG vs…”
BackgroundVijay, A., & Gertz, M. A. (2007) · Blood · doi:10.1182/blood-2006-11-055012 · Cited by 170
Idiopathic Systemic Capillary Leak Syndrome (Clarkson's Disease): The Mayo Clinic Experience
Kapoor, P., Greipp, P. T., Schaefer, E. W., Mandrekar, S. J., Kamal, A. H., Gonzalez-Paz, N. C., Kumar, S., & Greipp, P. R. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0159 · Cited by 176
Prevalence of Monoclonal Gammopathy of Undetermined Significance: A Systematic Review
Wadhera, R. K., & Rajkumar, S. V. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0337 · Cited by 171
Self-citationSrkalovic, G., Cameron, M. G., Rybicki, L., Deitcher, S. R., Kattke‐Marchant, K., & Hussein, M. A. (2004) · Cancer · doi:10.1002/cncr.20405 · Cited by 172
Metadata
- Authors
- Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Offord, J. R., Larson, D. R., Plevak, M. F., & Melton, L. J.
- Affiliations
- Mayo Clinic (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2002-02-21
- Volume
- 346
- Issue
- 8
- Pages
- 564-569
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2000655497
- Cited by
- 1,475
- References
- 17
- Citations by year
- 2026: 32 · 2025: 51 · 2024: 66 · 2023: 48 · 2022: 62 · 2021: 65 · 2020: 66 · 2019: 56 · 2018: 67 · 2017: 62 · 2016: 59 · 2015: 63 · 2014: 74 · 2013: 87 · 2012: 63
- FWCI
- 23.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (CA6 2242, P01CA062242)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Internal Medicine › Amyloidosis: Diagnosis, Treatment, Outcomes
- Keywords
- monoclonal gammopathy of undetermined significance, progression to multiple myeloma, prognosis, plasma cell neoplasms, AL amyloidosis, macroglobulinemia, chronic lymphocytic leukemia, plasmacytoma, smoldering multiple myeloma, bone marrow plasma cells, risk prediction
- MeSH terms
- Adult, Aged, Amyloidosis, Follow-Up Studies, Humans, Leukemia, Lymphoid, Lymphoma, Waldenstrom Macroglobulinemia, Middle Aged, Multiple Myeloma, Paraproteinemias, Probability, Prognosis, Risk Factors, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.